What is Tryngolza (olezarsen) and how is it used to treat hypertriglyceridemia?

What is Tryngolza (Olezarsen)?

Tryngolza (olezarsen) is an FDA-approved antisense oligonucleotide that targets apolipoprotein C-III (apoC-III) to dramatically lower triglycerides in adults with severe hypertriglyceridemia. 1

FDA-Approved Indications

Tryngolza is indicated as an adjunct to diet for two specific populations 1:

• Familial Chylomicronemia Syndrome (FCS): To reduce triglycerides in adults with this rare genetic disorder where the body cannot break down fats
• Severe Hypertriglyceridemia (sHTG): To reduce triglycerides ≥500 mg/dL AND reduce the risk of acute pancreatitis in adults

Mechanism of Action

Olezarsen works by blocking hepatic production of apoC-III mRNA, which increases triglyceride clearance from the bloodstream 2. This represents a fundamentally different approach than traditional triglyceride-lowering therapies.

Dosing and Administration

For FCS patients: 80 mg subcutaneously once monthly 1

For sHTG patients: Start with 50 mg subcutaneously once monthly. If the patient tolerates this dose and needs additional triglyceride reduction, increase to 80 mg once monthly 1

• Inject into the abdomen or front of thigh (back of upper arm only if given by healthcare provider/caregiver)
• Must be combined with a low-fat diet: ≤20 grams of fat per day for FCS patients 1
• If a dose is missed, take as soon as remembered and resume monthly dosing from that date 1

Efficacy Data

The most recent meta-analyses demonstrate robust triglyceride-lowering effects 3, 4, 5:

• Triglyceride reduction: 47-58% decrease (50 mg dose: -46.61%; 80 mg dose: -54.37%)
• ApoC-III reduction: 64-69% decrease
• Non-HDL-C reduction: 21-25% decrease
• VLDL-C reduction: 48-55% decrease
• ApoB reduction: 11-12% decrease
• HDL-C increase: 22-35% increase
• Acute pancreatitis risk reduction: 67-84% decrease 3, 4

These effects are dose-dependent, with the 80 mg dose providing greater triglyceride reduction than 50 mg 6.

Safety Profile

Critical Warnings 1:

1. Hypersensitivity Reactions: Serious reactions including bronchospasm, facial swelling, urticaria, chills, and myalgia have occurred. Stop Tryngolza immediately and seek medical attention if these develop.

2. Liver Enzyme Elevations: Increases in ALT/AST and hepatic fat accumulation can occur

   • Check liver enzymes before starting treatment or increasing dose
   • Monitor when clinically indicated
   • The 80 mg dose carries higher risk of ALT/AST ≥3× ULN (RR 2.56) 4
   • Discontinue immediately if serious hepatic injury with symptoms, hyperbilirubinemia, or jaundice occurs 1

Common Adverse Events 1:

• In FCS patients (>5% and >3% higher than placebo): Injection site reactions, decreased platelet count, arthralgia
• In sHTG patients (≥2% higher than placebo): Injection site reactions, liver enzyme increases

Important: Overall adverse events and serious adverse events are comparable to placebo 3, 4, 5. The medication appears generally well-tolerated with appropriate monitoring.

Clinical Context

Traditional guidelines emphasize statins as first-line therapy for cardiovascular risk reduction in hypertriglyceridemia 7. However, when triglycerides remain ≥500 mg/dL despite lifestyle modification and standard therapy, the primary concern shifts to pancreatitis prevention 7, 8. This is where Tryngolza fills a critical unmet need.

The 2021 ACC guidelines note that severe hypertriglyceridemia (≥500 mg/dL, especially ≥1,000 mg/dL) carries a 14% incidence of acute pancreatitis 7. Traditional pharmacotherapy has limited effectiveness at these extreme levels because these agents primarily reduce hepatic VLDL synthesis rather than clearing circulating chylomicrons 7.

Storage and Handling

• Store refrigerated at 2-8°C (36-46°F) in original carton 1
• Can be kept at room temperature 15-30°C (59-86°F) for up to 6 weeks
• Protect from light and heat
• Discard if not used within 6 weeks at room temperature 1

Contraindications

Do not use if: History of serious hypersensitivity reactions to olezarsen or any excipients 1

Monitoring Requirements

• Liver enzymes before initiation, before dose increases, and when clinically indicated 1
• Platelet counts (particularly in FCS patients) 1
• Watch for signs of liver injury: fatigue, anorexia, right upper quadrant discomfort, dark urine, jaundice 1

Key Clinical Pearls

• Tryngolza addresses a specific high-risk population where traditional therapies often fail
• The reduction in pancreatitis risk is clinically meaningful and evidence-based 3, 4
• Dose escalation from 50 mg to 80 mg in sHTG patients should be based on tolerability and need for additional triglyceride reduction
• Dietary fat restriction remains essential: This is not a medication that allows patients to abandon dietary management 1
• LDL-C may increase modestly with the 50 mg dose (17.58%) but this must be weighed against the dramatic triglyceride reduction and pancreatitis risk reduction 4